Logo image of PHXM

PHAXIAM Therapeutics SA (PHXM) Stock Fundamental Analysis

NASDAQ:PHXM - Nasdaq - US29604W2070 - ADR - Currency: USD

3.1  -0.02 (-0.64%)

After market: 3.1 0 (0%)

Fundamental Rating

2

PHXM gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. PHXM may be in some trouble as it scores bad on both profitability and health. PHXM does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

PHXM had negative earnings in the past year.
PHXM had a negative operating cash flow in the past year.
PHXM Yearly Net Income VS EBIT VS OCF VS FCFPHXM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 -20M -40M -60M

1.2 Ratios

The Return On Assets of PHXM (-0.35%) is better than 93.60% of its industry peers.
PHXM's Return On Equity of -0.62% is amongst the best of the industry. PHXM outperforms 93.94% of its industry peers.
Industry RankSector Rank
ROA -0.35%
ROE -0.62%
ROIC N/A
ROA(3y)-57.41%
ROA(5y)N/A
ROE(3y)-170.88%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PHXM Yearly ROA, ROE, ROICPHXM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PHXM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PHXM Yearly Profit, Operating, Gross MarginsPHXM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 -500 -1K -1.5K

More info and screens

2

2. Health

2.1 Basic Checks

PHXM does not have a ROIC to compare to the WACC, probably because it is not profitable.
PHXM has about the same amout of shares outstanding than it did 1 year ago.
PHXM has a better debt/assets ratio than last year.
PHXM Yearly Shares OutstandingPHXM Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 1M 2M 3M 4M 5M
PHXM Yearly Total Debt VS Total AssetsPHXM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 20M 40M 60M 80M

2.2 Solvency

PHXM has an Altman-Z score of -1.09. This is a bad value and indicates that PHXM is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -1.09, PHXM perfoms like the industry average, outperforming 52.36% of the companies in the same industry.
A Debt/Equity ratio of 0.30 indicates that PHXM is not too dependend on debt financing.
PHXM has a worse Debt to Equity ratio (0.30) than 71.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF N/A
Altman-Z -1.09
ROIC/WACCN/A
WACC4.88%
PHXM Yearly LT Debt VS Equity VS FCFPHXM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 0 20M -20M -40M

2.3 Liquidity

PHXM has a Current Ratio of 1.78. This is a normal value and indicates that PHXM is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.78, PHXM is not doing good in the industry: 80.13% of the companies in the same industry are doing better.
PHXM has a Quick Ratio of 1.78. This is a normal value and indicates that PHXM is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.78, PHXM is not doing good in the industry: 78.62% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.78
Quick Ratio 1.78
PHXM Yearly Current Assets VS Current LiabilitesPHXM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

PHXM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.68%, which is quite impressive.
Looking at the last year, PHXM shows a very strong growth in Revenue. The Revenue has grown by 59.04%.
EPS 1Y (TTM)99.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1025.16%
Revenue 1Y (TTM)59.04%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-70.86%

3.2 Future

PHXM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.84% yearly.
Based on estimates for the next years, PHXM will show a very negative growth in Revenue. The Revenue will decrease by -18.92% on average per year.
EPS Next Y77.73%
EPS Next 2Y36.72%
EPS Next 3Y23.84%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-18.92%

3.3 Evolution

PHXM Yearly Revenue VS EstimatesPHXM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M
PHXM Yearly EPS VS EstimatesPHXM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PHXM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PHXM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PHXM Price Earnings VS Forward Price EarningsPHXM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PHXM Per share dataPHXM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

PHXM's earnings are expected to grow with 23.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.72%
EPS Next 3Y23.84%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PHXM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHAXIAM Therapeutics SA

NASDAQ:PHXM (3/8/2024, 8:27:22 PM)

After market: 3.1 0 (0%)

3.1

-0.02 (-0.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2023-11-14/amc
Earnings (Next)03-20 2024-03-20/amc
Inst Owners0.01%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap18.83M
Analysts85
Price Target10.17 (228.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.8%
PT rev (3m)6.97%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-15.5%
EPS NY rev (3m)-0.34%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.6
P/FCF N/A
P/OCF N/A
P/B 0.47
P/tB 2.87
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)-1.04
Fwd EYN/A
FCF(TTM)-4.14
FCFYN/A
OCF(TTM)-4.12
OCFYN/A
SpS1.19
BVpS6.57
TBVpS1.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.35%
ROE -0.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-57.41%
ROA(5y)N/A
ROE(3y)-170.88%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.21%
Cap/Sales 1.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.78
Quick Ratio 1.78
Altman-Z -1.09
F-Score3
WACC4.88%
ROIC/WACCN/A
Cap/Depr(3y)10.07%
Cap/Depr(5y)N/A
Cap/Sales(3y)13.01%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1025.16%
EPS Next Y77.73%
EPS Next 2Y36.72%
EPS Next 3Y23.84%
EPS Next 5YN/A
Revenue 1Y (TTM)59.04%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-70.86%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-18.92%
EBIT growth 1Y51.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.84%
EBIT Next 3Y11.18%
EBIT Next 5YN/A
FCF growth 1Y44.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.05%
OCF growth 3YN/A
OCF growth 5YN/A